Safety and Efficacy Trial of a RNActive-Derived Prostate Cancer Vaccine in Hormone Refractory Disease.

Trial Profile

Safety and Efficacy Trial of a RNActive-Derived Prostate Cancer Vaccine in Hormone Refractory Disease.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 07 Jul 2015

At a glance

  • Drugs CV 9103 (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions
  • Sponsors CureVac
  • Most Recent Events

    • 07 Jul 2015 As per a CureVac media release, results from this trial were published in the Journal for ImmunoTherapy of Cancer.
    • 07 Jul 2015 Results published in a CureVac Media Release.
    • 26 Jul 2013 Planned end date changed from 1 Dec 2012 to Sep 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top